445 related articles for article (PubMed ID: 29135284)
1. Atezolizumab in urothelial bladder carcinoma.
Hamilou Z; Lavaud P; Loriot Y
Future Oncol; 2018 Feb; 14(4):331-341. PubMed ID: 29135284
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
Katz H; Wassie E; Alsharedi M
Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
4. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.
Koshkin VS; Grivas P
Curr Oncol Rep; 2018 Apr; 20(6):48. PubMed ID: 29644490
[TBL] [Abstract][Full Text] [Related]
5. Atezolizumab in invasive and metastatic urothelial carcinoma.
Crist M; Balar A
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1295-1301. PubMed ID: 28994323
[TBL] [Abstract][Full Text] [Related]
6. [Atezolizumab (Tecentriq
Bernard-Tessier A; Bonnet C; Lavaud P; Gizzi M; Loriot Y; Massard C
Bull Cancer; 2018 Feb; 105(2):140-145. PubMed ID: 29290331
[TBL] [Abstract][Full Text] [Related]
7. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
Hussain SA; Birtle A; Crabb S; Huddart R; Small D; Summerhayes M; Jones R; Protheroe A
Eur Urol Oncol; 2018 Dec; 1(6):486-500. PubMed ID: 31158093
[TBL] [Abstract][Full Text] [Related]
8. Methodological Considerations for Early-phase Development of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer.
Necchi A; Giardiello D; Mariani L
Eur Urol; 2017 May; 71(5):840-841. PubMed ID: 27720533
[No Abstract] [Full Text] [Related]
9. Durvalumab for the treatment of urothelial carcinoma.
Alsharedi M; Srivastava R; Elmsherghi N
Drugs Today (Barc); 2017 Dec; 53(12):647-652. PubMed ID: 29517083
[TBL] [Abstract][Full Text] [Related]
10. Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment.
Aoun F; Rassy EE; Assi T; Albisinni S; Katan J
Immunotherapy; 2017 Mar; 9(5):451-460. PubMed ID: 28357911
[TBL] [Abstract][Full Text] [Related]
11. #Checkmate: could checkpoint inhibitors be the game changer in the fight against metastatic urothelial carcinoma?
Dhariwal R; Pindoria N; Dasgupta P; Khan MS
BJU Int; 2019 Feb; 123(2):203-207. PubMed ID: 29974606
[No Abstract] [Full Text] [Related]
12. The current status of checkpoint inhibitors in metastatic bladder cancer.
Fahmy O; Khairul-Asri MG; Stenzl A; Gakis G
Clin Exp Metastasis; 2016 Oct; 33(7):629-35. PubMed ID: 27380916
[TBL] [Abstract][Full Text] [Related]
13. Emerging role of checkpoint inhibition in localized bladder cancer.
Singh P; Black P
Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
[TBL] [Abstract][Full Text] [Related]
14. Role of Checkpoint Inhibition in Localized Bladder Cancer.
Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
16. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of immunotherapy in urothelial carcinoma-Advanced disease.
Zibelman M; Ramamurthy C; Plimack ER
Urol Oncol; 2016 Dec; 34(12):538-547. PubMed ID: 27888981
[TBL] [Abstract][Full Text] [Related]
18. Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.
Eckstein M; Erben P; Kriegmair MC; Worst TS; Weiß CA; Wirtz RM; Wach S; Stoehr R; Sikic D; Geppert CI; Weyerer V; Bertz S; Breyer J; Otto W; Keck B; Burger M; Taubert H; Weichert W; Wullich B; Bolenz C; Hartmann A; Erlmeier F
Eur J Cancer; 2019 Jan; 106():234-243. PubMed ID: 30528808
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy Advances in Urothelial Carcinoma.
Jain RK; Snyders T; Nandagopal L; Garje R; Zakharia Y; Gupta S
Curr Treat Options Oncol; 2018 Dec; 19(12):79. PubMed ID: 30554335
[TBL] [Abstract][Full Text] [Related]
20. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.
Faiena I; Cummings AL; Crosetti AM; Pantuck AJ; Chamie K; Drakaki A
Drug Des Devel Ther; 2018; 12():209-215. PubMed ID: 29416316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
